• newly diagnosed1
• relapsed/refractory2

• Protocols

• AALL1732

  OPEN TO ACCRUAL

  Phase 3 Inotuzumab Ozogamicin for Newly Dx HR B ALL plus MPAL and Disseminated B LLy
  
  

• APAL2020SC

  OPEN TO ACCRUAL

  PedAL Screening Trial - Developing new therapies for Relapsed Leukemias.